Biogen (BIIB) 주식 개요
는 미국, 유럽, 독일, 아시아 및 전 세계에서 치료제를 발견, 개발, 제조 및 공급하고 있습니다. 자세히 보기
BIIB Community Fair Values
Create NarrativeSee what 107 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Biogen Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$193.76 |
| 52주 최고가 | US$205.97 |
| 52주 최저가 | US$121.05 |
| 베타 | 0.19 |
| 1개월 변동 | 5.09% |
| 3개월 변동 | -0.70% |
| 1년 변동 | 54.01% |
| 3년 변동 | -35.12% |
| 5년 변동 | -27.56% |
| IPO 이후 변동 | 6,184.11% |
최근 뉴스 및 업데이트
Recent updates
내러티브 업데이트 • May 04
BIIB: 2026 Readouts In Neurology And Immunology Will Drive Upside Potential
Analysts have lifted Biogen's fair value estimate by about $18 to $273.20 as they factor in updated revenue growth assumptions, a higher future P/E, and recent price target revisions across the Street. Analyst Commentary Recent Street research around Biogen has leaned constructive, with a cluster of fresh price target adjustments and several rating upgrades pointing to improving sentiment on execution and long term growth potential.
내러티브 업데이트 • Apr 20
BIIB: 2026 Trial Outcomes Will Likely Undermine Recent Acquisition Optimism
Analysts made a slight upward adjustment to Biogen's fair value estimate to about $151, reflecting a blend of higher and lower price target revisions related to recent acquisition activity, pipeline updates, and shifting views on its long term earnings profile. Analyst Commentary Recent Street research around Biogen has been active, with a mix of higher and lower price targets clustered around the company’s acquisition activity, pipeline readouts, and changing expectations for longer term earnings power.Seeking Alpha • Apr 06
Revisiting Eisai And Biogen's Leqembi Data For Alzheimer's Disease
Summary Eisai (ESALF) and Biogen (BIIB) have presented inconsistent efficacy claims for Leqembi in Alzheimer's, particularly regarding APOE4 genetic subgroups. Real-world data may reveal Leqembi is only marginally effective for APOE4 single-copy carriers, with little benefit for non-carriers or double-copy carriers. BIIB may be more resilient than ESALF to negative Leqembi developments due to pipeline diversity, but no near-term catalysts are evident for BIIB stock movement. Efforts to expand Leqembi’s market may be misguided; regulatory scrutiny and emerging alternatives could further limit its commercial potential. Read the full article on Seeking Alpha내러티브 업데이트 • Apr 05
BIIB: 2026 Clinical Outcomes Will Likely Challenge Recent Neuroscience Optimism
The analyst price target for Biogen has been adjusted slightly to $150. This reflects recent model updates that incorporate a modestly higher discount rate, slightly lower revenue growth assumptions, a small uptick in expected profit margins, and Street research focusing on price target changes and evolving views on the company's pipeline and neurology portfolio.
새로운 내러티브 • Mar 31
Biogen Inc. (BIIB): The "Post-MS" Pivot and the Alzheimer’s Momentum
Biogen Inc. (BIIB) is navigating a high-stakes transition year in 2026, closing the March 31, 2026, session at $178.98 USD on the NASDAQ.내러티브 업데이트 • Mar 22
BIIB: 2026 Clinical Readouts Will Likely Undermine Recent Pipeline Optimism
Analysts have nudged Biogen's fair value estimate higher to $151.48 from $147.47, reflecting a series of recent price target increases across the Street and ongoing reassessments of the company's pipeline and commercial outlook. Analyst Commentary Recent Street research around Biogen points to a mixed setup, with several firms adjusting price targets and ratings as they reassess the pipeline, commercial execution, and sector positioning.
내러티브 업데이트 • Mar 07
BIIB: 2026 Clinical Readouts And Easing Policy Risks Will Drive Upside
The analyst fair value estimate for Biogen has increased by about $16 to $205.67 as analysts factor in recent price target revisions and updated views on the pipeline and commercial outlook. Analyst Commentary Recent research updates on Biogen cluster around revisions to price targets, refreshed models on the pipeline, and differing expectations for execution in 2026 and beyond.내러티브 업데이트 • Feb 21
BIIB: 2026 Clinical Readouts Will Likely Expose Pipeline Execution Risk
The analyst price target for Biogen has been raised from $143.00 to $147.47. Analysts point to a stronger profit margin outlook and updated pipeline and commercial assumptions as key drivers of the change.분석 기사 • Feb 13
There May Be Reason For Hope In Biogen's (NASDAQ:BIIB) Disappointing Earnings
Shareholders appeared unconcerned with Biogen Inc.'s ( NASDAQ:BIIB ) lackluster earnings report last week. We think...내러티브 업데이트 • Feb 07
BIIB: 2026 Clinical Readouts And Pipeline Execution Will Drive Upside Potential
Analysts have nudged their price targets on Biogen higher, with our fair value estimate rising to about $255.45 from $247.88 as they update models for revenue growth, margins, and a modestly richer future P/E multiple following a series of mixed but generally upward target revisions across the Street. Analyst Commentary Recent research on Biogen has been mixed, but the pricing and modeling changes skew toward a constructive tone.내러티브 업데이트 • Jan 23
BIIB: 2026 Clinical Readouts Will Test Lofty Pipeline Expectations
Analysts have raised their Biogen fair value estimate from $128.00 to $143.00, citing refreshed models and higher Street price targets as they incorporate updated views on the pipeline, sector conditions, and 2026 catalysts. Analyst Commentary Street research around Biogen points to a generally more constructive view on the shares, with several firms lifting price targets into a range between about $180 and $225.내러티브 업데이트 • Jan 09
BIIB: Easing Policy Shifts And 2026 Pipeline Readouts Will Shape Outlook
Narrative Update: Biogen (BIIB) Biogen's fair value estimate has moved from about $181 to around $190 as analysts lift price targets into the $180 to $225 range and highlight updated models, slightly better margin and growth assumptions, and potential pipeline and sector catalysts through 2026. Analyst Commentary Recent research updates on Biogen cluster around a tighter valuation band in the high US$100s to low US$200s, with most firms revisiting their models and assumptions for 2025 to 2026.내러티브 업데이트 • Dec 24
BIIB: Easing Policy Overhangs And Alzheimer’s Data Will Shape Risk Reward Balance
Analysts have modestly raised their price target on Biogen, now implying upside in line with a slightly higher fair value of approximately $181, citing easing policy overhangs and a partial rerating of large-cap biopharma as investor focus shifts back to fundamentals. Analyst Commentary Street research on Biogen has turned incrementally more constructive, with several firms lifting price targets as macro and policy risks appear less threatening to the sector.내러티브 업데이트 • Dec 10
BIIB: Policy Environment And Late-Stage Pipeline Will Shape Risk And Reward Ahead
Analysts have modestly increased their price target for Biogen, lifting fair value by about $1 to roughly $179 per share. They cite easing policy overhangs, growing confidence in 2025 to 2026 fundamentals, and potential upside from Leqembi and the broader late stage pipeline.내러티브 업데이트 • Nov 26
BIIB: Policy Shifts And Drug Pipeline Progress Will Influence Risk And Reward Ahead
Biogen's analyst price target has been increased modestly, with the fair value estimate rising from $176.72 to $178.07. Analysts point to easing policy headwinds and renewed focus on company fundamentals amid recent sector re-ratings.내러티브 업데이트 • Nov 12
BIIB: Pipeline And Policy Developments Will Shape Risk And Reward Into 2025
Analysts have raised their price target for Biogen by approximately $4 to $176.72, citing improving sector fundamentals, easing policy risks, and a favorable risk/reward outlook as reasons for the adjustment. Analyst Commentary Recent street research on Biogen provides insight into both the optimistic and cautious perspectives that currently shape the stock's outlook.내러티브 업데이트 • Oct 29
Easing Policy Risks And New Therapy Launches Will Drive Shares Higher
Analysts have slightly raised their price target for Biogen to $172.55 from $172.34, reflecting modestly improved revenue growth expectations and an easing policy backdrop in the biotech sector. Analyst Commentary Recent street research reveals a spectrum of opinions around Biogen, highlighted by both bullish and bearish analyst actions.내러티브 업데이트 • Oct 15
Expanding Global Healthcare And Diagnostics Infrastructure Will Drive Future Growth
Analysts have slightly lifted their price targets for Biogen, with the updated fair value estimate rising from $170.03 to $172.34. This reflects improved profit margin expectations and easing industry headwinds cited in recent research updates.내러티브 업데이트 • Sep 20
Expanding Global Healthcare And Diagnostics Infrastructure Will Drive Future Growth
Biogen's modestly reduced consensus price target reflects a balanced analyst view, with optimism around strong Q2 performance, pipeline progress, and portfolio refocusing offset by lingering regulatory overhangs and a muted near-term growth outlook, resulting in a slight decrease in fair value from $171.96 to $170.03. Analyst Commentary Bullish analysts cite strong Q2 performance, particularly from Leqembi and the MS franchise, as well as solid sales across other programs as drivers for raised price targets.내러티브 업데이트 • Sep 05
Expanding Global Healthcare And Diagnostics Infrastructure Will Drive Future Growth
Biogen’s consensus price target was modestly raised as analysts highlighted strong Q2 performance, advancements in its neuro portfolio and pipeline, and ongoing portfolio refocusing, offsetting medium-term growth concerns and regulatory risks; the new fair value is now $171.96. Analyst Commentary Bullish analysts highlight strong Q2 performance, particularly in Leqembi and the MS franchise, combined with solid sales across other programs, supporting upward revisions in price targets.분석 기사 • Jun 17
Biogen (NASDAQ:BIIB) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Apr 25
Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent?
Summary Biogen Inc.'s earnings and share price have declined due to falling Multiple Sclerosis treatment revenue; new drugs and pipeline show promise but haven't offset losses yet. Biogen's Multiple Sclerosis treatments face patent expirations and competition, pressuring revenue; new Alzheimer's Disease and rare disease treatments could drive future growth. Financially, Biogen remains profitable with strong FCF, but reduced R&D spending and lack of insider buying or share buybacks are concerning. I rate BIIB stock a hold due to current uncertainties; will reconsider upon sustained revenue growth, regulatory approvals, or positive trial data. Read the full article on Seeking AlphaSeeking Alpha • Mar 27
Biogen: Balancing Risks And Opportunities
Summary Biogen's new management is diversifying its product portfolio and optimizing costs, but faces significant risks from market share loss and generic competition. The fair valuation of Biogen shares is $149, close to the current price, leading to a "Hold" rating and a recommended purchase price of $115-120. Key growth drivers include potential success with Leqembi, Skyclarys, and optimization efforts, while risks involve slow sales of new products and competition. Despite a 35% stock price drop in 2024, Biogen's strategic steps and increased margins suggest shares are near fair value. Read the full article on Seeking AlphaSeeking Alpha • Feb 15
Biogen Q4 Earnings Review: Why I'm Calling Time On This 'Powder Puff' Pharma
Summary Biogen's Q4 2024 earnings showed slight revenue growth but Wall Street remains unimpressed due to weak guidance and declining key drug franchises. Leqembi's commercial performance is disappointing, mirroring Aduhelm's failure, and Biogen's pipeline lacks promising products to drive future growth. The multiple sclerosis franchise is in decline, and new drug approvals like Qalsody and Skyclarys have shown minimal revenue impact. Biogen's strategic missteps, including the failed Sage Therapeutics acquisition, underscore a lack of innovation and direction, leading to a "sell" rating. Read the full article on Seeking Alpha주주 수익률
| BIIB | US Biotechs | US 시장 | |
|---|---|---|---|
| 7D | 1.0% | 3.1% | 1.2% |
| 1Y | 54.0% | 34.6% | 28.7% |
수익률 대 산업: BIIB은 지난 1년 동안 34.6%의 수익을 기록한 US Biotechs 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: BIIB은 지난 1년 동안 28.7%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| BIIB volatility | |
|---|---|
| BIIB Average Weekly Movement | 4.8% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
안정적인 주가: BIIB는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: BIIB의 주간 변동성(5%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1978 | 7,500 | Chris Viehbacher | www.biogen.com |
는 미국, 유럽, 독일, 아시아 및 전 세계에서 치료제를 발견, 개발, 제조 및 공급하고 있습니다. 이 회사는 다발성 경화증(MS) 치료제 테크피데라, 뷰메리티, 아보넥스, 플레그리디, 티사브리, 척수성 근위축증 치료제 스핀라자, 프리드리히 운동실조증 치료제 스카이클라리스, 근위축성 측색 경화증 치료제 퀄소디를 공급하고 있습니다; 판상 건선 치료제 후마덤, 에타너셉트 바이오시밀러 엔브렐의 베네팔리, 아달리무맙 바이오시밀러 휴미라의 임랄디, 인플릭시맙 바이오시밀러 레미케이드의 플릭사비, 판상 건선 치료제 아달리무맙 바이오시밀러 휴미라, 판상 건선 치료제 아달리무맙의 플릭사비, 판상 건선 치료제 엔브렐의 베네팔리, 판상 건선 치료제 휴미라, 판상 건선 치료제 휴미라. 알츠하이머병 치료제 레켐비, 산후 우울증 치료제 주르주베, 비호지킨 림프종, 만성 림프구성 백혈병(CLL), 류마티스 관절염, 두 가지 형태의 ANCA 연관 혈관염, 천포창 치료를 위한 리툭산도 제공합니다; 비호지킨 림프종 및 CLL 치료제 '리툭산 하이셀라', CLL 및 여포형 림프종 치료제 '가지바', 재발성 다발성경화증 및 원발성 진행성 다발성경화증 치료제 '오크리버스', 재발성 또는 불응성 여포형 림프종 치료제 '룬수미오', 재발 또는 불응성 미만성 거대 B세포 림프종 치료제 '글로피타맙' 및 기타 항 CD20 치료제를 개발하고 있습니다.
Biogen Inc. 기초 지표 요약
| BIIB 기초 통계 | |
|---|---|
| 시가총액 | US$28.61b |
| 순이익 (TTM) | US$1.37b |
| 매출 (TTM) | US$9.94b |
20.9x
주가수익비율(P/E)2.9x
주가매출비율(P/S)BIIB는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| BIIB 손익계산서 (TTM) | |
|---|---|
| 매출 | US$9.94b |
| 매출원가 | US$2.11b |
| 총이익 | US$7.82b |
| 기타 비용 | US$6.45b |
| 순이익 | US$1.37b |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | 9.29 |
| 총이익률 | 78.72% |
| 순이익률 | 13.81% |
| 부채/자본 비율 | 33.7% |
BIIB의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/25 00:26 |
| 종가 | 2026/05/22 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Biogen Inc.는 58명의 분석가가 다루고 있습니다. 이 중 22명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| David Toung | Argus Research Company |
| Brian Skorney | Baird |
| Emily Field | Barclays |